Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proline-rich protein 23A (PRR23A) is a human protein encoded by the *PRR23A* gene found on chromosome 3q23[1]. This protein is categorized as a proline-rich protein due to its high proline content, but its biological role and druggability remain poorly characterized in the literature. Proline-rich protein 23A is a 266 amino acid protein with a molecular weight of 28.2 kDa and a predicted isoelectric point of 4.57[1]. It is highly enriched in proline and is principally classified as a proline-rich protein. The *PRR23A* gene has only one exon and does not undergo alternative splicing in humans. Its expression has been detected primarily in the ovary, suggesting tissue-specific or enriched function[1]. The protein is largely disordered, with some predicted beta-strand and alpha-helix secondary structures, and there is a potential transmembrane domain, but its cellular function and role are unverified. Subcellular localization studies show presence in both the membrane and cytoplasm, with signals that may target the protein to the ER, nucleus, and mitochondria[1]. The protein interacts—according to co-expression and text mining—with a small set of proteins, primarily members of the beta-defensin family (DEFB106A, DEFB107A, DEFB105A, DEFB106B) and other proteins such as IQCJ, SPAG11B, and USP17L4, but these interactions are not well-confirmed experimentally[1]. No data currently support a defined physiological or pathological role, drug interactions, or involvement in human disease. PRR23A does not match criteria for canonical therapeutic targets, such as receptors, enzymes, transporters, or transcription factors, and there is no evidence to suggest the protein itself has utility as a drug target, biomarker, or therapeutic agent[1]. No misspelling or clear errors are associated with this entry, but it is important to note that little is known about its biology or disease relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proline-rich protein 23A (PRR23A).